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Chimeric antigen receptor T‑cell therapy
in glioblastoma: charging the T cells to fight
Craig A. Land1, Phillip R. Musich1, Dalia Haydar2, Giedre Krenciute2 and Qian Xie1,3*

Abstract
Glioblastoma multiforme (GBM) is the most common malignant brain cancer that invades normal brain tissue and
impedes surgical eradication, resulting in early local recurrence and high mortality. In addition, most therapeutic
agents lack permeability across the blood brain barrier (BBB), further reducing the efficacy of chemotherapy. Thus,
effective treatment against GBM requires tumor specific targets and efficient intracranial drug delivery. With the most
recent advances in immunotherapy, genetically engineered T cells with chimeric antigen receptors (CARs) are becoming a promising approach for treating cancer. By transducing T lymphocytes with CAR constructs containing a tumorassociated antigen (TAA) recognition domain linked to the constant regions of a signaling T cell receptor, CAR T cells
may recognize a predefined TAA with high specificity in a non-MHC restricted manner, and is independent of antigen
processing. Active T cells can travel across the BBB, providing additional advantage for drug delivery and tumor targeting. Here we review the CAR design and technical innovations, the major targets that are in pre-clinical and clinical
development with a focus on GBM, and multiple strategies developed to improve CAR T cell efficacy.
Keywords: Chimeric antigen receptors, CAR, T-cell therapy, Glioblastoma, Cellular immunotherapy
Background
Glioblastoma (GBM), WHO grade IV glioma, is the most
devastating brain tumor in adults [1]. The intrinsic capability of single tumor cells to invade normal brain tissue impedes surgical eradication, predictably resulting
in early local recurrence and death. Current treatment
options for GBM include maximal surgical removal,
radiotherapy and chemotherapy. However, the overall
survival rate has not changed significantly over the past
decade.
Adoptive cell transfer (ACT) using autologous lymphocytes for treating cancer started in 1988 with metastatic melanoma patients [2]. While early trials reported
an overall response in approximately 34% of patients [3],
subsequent studies demonstrated that lymphodepletion
prior to ACT may significantly improve the response
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rates to about 50% of patients [4, 5]. During the same
period, genetically engineered T cell receptors (TCR)
were explored to achieve robust T cell responses which
ultimately led to the emergence of chimeric antigen
receptor (CAR) T-cell therapy [6, 7]. In 2017, CD19-CAR
(tisagenlecleucel) became the first FDA-approved CAR-T
cell therapy for treating patients with relapsed or refractory B cell acute lymphoblastic leukemia (ALL) [8].
The first ACT-based attempts for GBM therapy started
about 40 years ago when several case reports showed that
autologous leukocyte infusion into the resection cavity at
the time of tumor resection may improve patient’s survival without toxicity [9–11]. However, these approaches
lacked specificity. To overcome this, genetic engineered
T cells have been generated to specifically target brain
tumor associated antigens (TAA) and have shown
promising pre-clinical results. For GBM, interleukin-13
receptor alpha 2 (IL13Rα2) became the first CAR T-cell
target tested in the clinic for its specific overexpression in tumors but not in normal tissues [12]. Epidermal
growth factor receptor variant III (EGFRvIII) [13], human

© The Author(s) 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and
the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material
in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material
is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the
permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativeco
mmons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/
zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Land et al. J Transl Med

(2020) 18:428

epidermal growth factor 2 (HER2) [14] and erythropoietin-producing hepatocellular carcinoma A2 (EphA2) [15]
were also developed as major targets for their overexpression in GBM but not in healthy brain tissues. Other
newly developed targets include ganglioside 2 (GD2) [16,
17], B7-H3 [18] and chlorotoxin [19]. Although all these
targets have shown promising preclinical results and are
evaluated in clinical trials (see Table 1 for summary), lack
of clinical efficacy indicates that genetic modifications
and therapeutic combinations are required in order to
achieve a better response. In this review, we will introduce the basic CAR structures and their optimizations,
the major targets that are in pre-clinical and clinical
development for targeting GBM, and the combination
strategies to improve CAR T-cell efficacy.

CAR designs and optimization
Conventional CARs

T cells play an essential role in cell-mediated immune
responses. T cell activation requires two signals: (i)
TCRs recognize and bind to the antigen peptides presented on the major histocompatibility complex (MHC)
exposed on the surface of antigen-presenting cells or
tumor cells, and (ii) T cell co-stimulatory signaling modules, such as CD28, 4-1BB and OX40, which bind to the
ligands expressed on antigen-presenting cells. It is well
accepted that T cells play a crucial role in immune surveillance, a function to detect and eliminate tumor cells
from the host. Compared to the TCR (Fig. 1a), a CAR
is a synthetic molecule designed to express an antigen
recognition domain which is usually a single-chain variable fragment (scFv) or a ligand specific for one TAA [20,
21]. This ectodomain is linked via a hinge and spacer to
the transmembrane domain and an intracellular signaling domain. The endodomain of the CAR consists of
CD3ζ activation domain (1st generation CAR) and one
or two co-stimulatory domain such as CD28, 4-1BB, or
OX40 (2nd or 3rd generation CAR). While first generation CAR T cells had limited longevity and tumor killing
efficacy in vivo [6], the second and third generation CAR
T cells showed improved proliferation and effector function [22]. The 4th generation of CARs further compose
additional genetic modifications that allow the release of
transgenic proteins of interest (POI), such as cytokines,
to enhance the CAR T cell expansion and survival [23]
(Fig. 1b). Most importantly, with this design, CAR T cell
can be re-directed to target specific tumor cells via T cellmediated multi-functional killing activities independent
of MHC expression levels (Fig. 1c). Loss of MHC class I
expression in tumor cells is a common mechanism leading to tumor escape and resistance to T cell immunity
[24]. The fact that CAR T cells can recognize and bind
to the TAAs unrestricted to MHC class I expression is
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making the CAR T-cell therapy an attractive approach for
anti-cancer therapeutics.
Universal CARs

CAR T cells are showing promising anti-tumor activity
against solid and brain tumors, however, the generation
of a CAR targeting a novel tumor antigen is complicated
and time consuming. It is well established that every
new antigen-recognition domain has to be tested with
multiple co-stimulatory domains. Even if well-defined
and characterized, signaling domains might not be fully
functional when testing with a new antigen-recognition
domain. In addition, multiple studies show that the hinge
and transmembrane domains also influence the function
of an antigen-specific CAR T cell [25–27]. One way to
overcome these challenges is to create a universal CAR
(uCAR). Indeed, several groups have reported generation
of uCARs. By engineering the CAR vector to express an
antigen-recognition domain specific for fluorescein isothiocyanate (FITC), Tamada et al. [28] has reported an
anti-FITC uCAR which further binds to FITC-tagged
monoclonal antibody specific to HER2, or CD20 (Fig. 2a).
Most importantly, the activity of the anti-FITC uCAR
can be attenuated by additional injection of FITC-IgG,
thus providing a safety switch when the risk of toxicity increases. Their study demonstrates that anti-tag
CAR may elicit a potent anti-tumor activity in vitro and
in vivo. However, it is not clear if such a design affects
CAR T cell effector function when compared to a conventional CAR design.
Another uCAR study by Cho et al. [29] reported a
split, universal and programmable (SUPRA) CAR system
(Fig. 2b). This is a two-component system: one component is a zipFv that contains a TAA-specific scFv that is
linked to a leucine zipper (AZip); the other component is
a CAR T cell that contains an extracellular leucine zipper
(BZip) plus a transmembrane domain and an intracellular signaling domain (zipCAR) (Fig. 2b). After the scFv
domain of the zipFv recognizes and binds to the specific
TAA on tumor cells, the BZip on the zipCAR T cells can
bind the AZip leucine zipper of the zipFv, leading to a
fully functional CAR T-cell activation and signaling. Similar to the anti-FITC uCAR, the activity of zipCAR can be
attenuated by subsequent injection of the AZip peptide.
With this design, the authors generated a SUPRA CAR
specific for HER2 which showed potent tumor killing
activity in solid tumor settings. Moreover, they further
modified this system to target multiple antigens.
While both groups demonstrated their uCAR systems
for targeting HER2 experimentally, brain tumor-specific
studies are warranted to evaluate whether uCARs are
feasible for clinical use, given a very complex and hostile brain tumor microenvironment. In addition, the
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Table 1 Recent clinical trials of CAR T-cell therapy in glioblastoma (in alphabetical order)
Target

Study title

Phase Status

Institution and location

Pilot study of B7-H3 CAR-T in treating patients
with recurrent and refractory glioblastoma.
NCT04385173

1

Recruiting

Second Affiliated Hospital, School of Medicine,
Zhejiang University, China

B7-H3 CAR-T for recurrent or refractory glioblastoma. NCT04077866

1/2

Recruiting

Second Affiliated Hospital, School of Medicine,
Zhejiang University, China

Chlorotoxin Chimeric antigen receptor (CAR) T cells with a
cholrotoxin tumor-targeting domain for the
treatment of M
 PP2+ recurrent or progressive
glioblastoma. NCT04214392

1

Recruiting

City of Hope Medical Center, CA, United States

EGFRvIII

CAR T cell receptor immunotherapy targeting
EGFRvIII for patients with malignant gliomas
expressing EGFRvIII. NCT01454596

1/2

Completed

National Institutes of Health Clinical Center, United
States

Intracerebral EGFR-vIII CAR-T cells for recurrent
GBM. NCT03283631

1

Suspended

Duke University Medical Center, NC, United States

Pilot study of autologous anti-EGFRvIII CAR T
cells in recurrent glioblastoma multiforme.
NCT02844062

1

Unknown status

Sanbo Brain Hospital Capital Medical University,
Beijing, China

Memory-enriched T cells in treating patients
with recurrent or refractory grade III–IV glioma.
NCT03389230

1

Recruiting

City of Hope Medical Center, CA, United States

EphA2

CAR-T cell immunotherapy for EphA2 positive
malignant glioma patients. NCT02575261

1/2

Withdrawn

Central Laboratory in Fuda Cancer Hospital, Guangdong, China

GD2

C7R-GD2.CAR T cells for patients with GD21
expressing brain tumors (GAIL-B). NCT04099797

Recruiting

Baylor College of Medicine, TX, United States

Personalized chimeric antigen receptor T cell
immunotherapy for patients with recurrent
malignant gliomas. NCT03423992

1

Recruiting

Xuanwu Hospital, Beijing, China

Intracranial injection of NK-92/5.28.z cells in
patients with recurrent HER2-positive glioblastoma. NCT03383978

1

Recruiting

Senckenberg Institute of Neurooncology, Frankfurt,
Germany

CMV-specific cytotoxic T lymphocytes expressing CAR targeting HER2 in patients with GBM.
NCT01109095

1

Completed

Baylor College of Medicine, TX, United States

Genetically modified T cells in treating patients
with recurrent or refractory malignant glioma.
NCT02208362

1

Recruiting

City of Hope Medical Center, CA, United States

Completed

City of Hope Medical Center, , CA, United States

CAR T-cell therapy
B7-H3

HER2

IL13Ra2

Phase I study of cellular immunotherapy for recur- 1
rent/refractory malignant glioma using intratumoral infusions of GRm13Z40-2, an allogeneic
CD8+ cytolitic T-cell line genetically modified
to express the IL 13-Zetakine and HyTK and to
be resistant to glucocorticoids, in combination
with interleukin-2. NCT01082926
CAR T-cell therapy in combination with chemotherapy
EGFRvIII

Immunogene-modified T (IgT) cells against glioblastoma multiforme. NCT03170141

1

Enrolling by invitation Shenzhen Geno-immune Medical Institute, Guangdong, China

CAR T-cell therapy in combination with immune check point inhibitors
EGFRvIII

CART-EGFRvIII + pembrolizumab in GBM.
NCT03726515

1

Active, not recruiting

Abramson Cancer Center of the University of Pennsylvania, PA, United States

IL13Ra2

IL13Ralpha2-targeted chimeric antigen receptor
(CAR) T cells with or without nivolumab and
ipilimumab in treating patients with recurrent
or refractory glioblastoma. NCT04003649

1

Recruiting

City of Hope Medical Center, CA, United States

Most recent GBM CAR-T cell therapy clinical trials were searched at www.Clinicaltrials.gov (2010 to present)
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Fig. 1 Basic principle of CAR structure and CAR T-cell therapy. a T-cell receptor (TCR) complex. The TCR-CD3 complex contains variable TCR-α and
TCR-β chains coupled to three dimeric signaling transduction modules CD3 δ/ε, CD3 γ/ε and CD3 ζ/ζ. T cell activation starts when the TCR binds to
the antigen/MHC peptide on the surface of antigen-presenting cells or tumor cells. b Basic 1st–4th generation design of chimeric-antigen receptors
(CAR). The ectodomain of the CAR is composed of an antigen-binding region (scFv), a hinge and a spacer. The transmembrane portion links the
ectodomain to the intracellular endodomain. The endodomain contains a CD3ζ signaling domain (1st generation) and one or two costimulatory
domains (2nd and 3rd generation, respectively). The 4th generation CARs (also called TRUCKs) contain an additional expression vector or a
transgene to express a synthetic protein of interest (POI), for instance cytokines and chemokines. c Mechanism of CAR T-cell therapy. CAR T cells use
the scFv domain of the CAR to recognize and bind to the tumor-associated antigen (TAA) on the tumor cell surface. This binding activates CAR T
cells signaling through the endodomain CD3ζ module which elicits cytotoxic functions by producing perforins, granzymes and cytokines

biological activity of a uCAR requires a stable complex
formed by three components instead of two in traditional
CARs, raising the concerns of stability and functional
activities when tested in vivo. Finally, future studies
should evaluate carefully the safety of uCARs as both systems contain immunogenic molecules such as FITC and
leucine zippers.
CARs targeting multiple antigens

Despite the increasing number of targets being tested in
clinical trials (Table 1), CAR T cells have failed to completely eradicate brain tumors. A major limitation of a

single-antigen targeting CAR T-cell therapy for GBM is
the inherent heterogeneity and plasticity of the tumor
cells, allowing some cells to escape CAR T cell killing
due to the loss of the targeted antigen. As a result, single
antigen-targeting CAR T cells fail to completely eradicate brain tumors resulting in antigen-negative relapses
as demonstrated by pre-clinical and clinical studies [30].
Such relapses prompted investigators to devise strategies
and design CARs that can target multiple TAAs, including bi-specific, trivalent, tandem, split, and synNotch
CARs (Fig. 2c–g). Among them, the first three strategies
have been explored for targeting brain tumors.
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Fig. 2 Optimized CAR designs. a The anti-tag uCAR is designed to express an antigen recognition domain specific for a tag (often FITC) molecule
attached to a monoclonal antibody specific to the TAA on the surface of tumor cells. b SUPRA CAR is composed of two parts: the zipFv component
consists of a scFv specific for the TAA to be targeted and a leucine zipper (AZip). The second component is zipCAR-T cell expressing a CAR with
an extracellular leucine zipper (BZip). The zipFv binds to the TAA via the scFv domain and to the zipCAR via binding of the AZip and BZip leucine
zipper domains, leading to CAR T cell activation. c, d Bi-specific or trivalent CAR T cells are designed to co-express two or three CARs within the
same cell that are directed to two or three different brain TAAs, respectively. Alternatively, two or three different CAR T cell populations could be
pooled together to simultaneously target multiple TAAs on the tumor cell surface. e Tandem CAR is composed of two or more scFvs in tandem
followed by hinge, transmembrane and signaling domains. Binding of either one or more TAAs may fully activate T cell signaling and function. f
Split CAR is designed to co-express two different CARs for targeting two different TAAs. One CAR contains the CD3ζ signal and the other contains
the co-stimulation signal. Binding to both TAAs is required for CAR T cell activation. g The activation of a synNotch CAR T cell requires two TAAs be
present on the cancer cell surface and occurs in two steps: (1) the synNotch receptor recognizes and binds to the first antigen, leading to release of
a transcription activator for the CAR transcription; and (2) the CAR recognizes and binds to the second antigen, leading to full CAR T cell activation.
Only when both antigens are present will the T cells be activated and kill the target tumor cells

Bi-specific CAR T cells are generated by either double
transduction of two CARs that are directed against two
different brain TAA (co-expression) or by pooling two

different CAR T cell populations (pooled CAR T cells)
(Fig. 2c). Hedge et al. [31] generated T cells by (i) individually expressing HER2- and IL13Ra2-specific CARs or
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(ii) co-expressing both CARs, one targeting each antigen.
They revealed that both approaches elicit an adequate
anti-tumor response and, most importantly, prevented
antigen escape in GBM in vitro and in vivo. Moreover,
T cells co-expressing HER2- and IL13Ra2-CARs showed
better anti-tumor response when compared to T cells
individually expressing both CARs. The same group took
it a step further and designed a trivalent CAR structure
which encodes three full CAR molecules in one construct
(Fig. 2d). Thus, a single transduction allowed them to
express three different, separate CARs simultaneously in
one T cell. In their study, using this method, Bielamowicz et al. [32] reported a trivalent CAR T-cell system for
co-targeting HER2, IL13Ra2, and EphA2; the trivalent
CAR T-cell therapy lead to a significantly better overall
survival in vivo when compared to dual and single CAR
T cells when tested in patient derived xenograft models.
Another multi-antigen targeting approach, also established by the same group, is the tandem CAR (TanCAR).
Here, the CAR is composed of multiple scFvs placed in
tandem followed by hinge, transmembrane and signaling
domains (Fig. 2e). Hedge et al. [33] reported the development of a TanCAR designed to target HER2 and IL13Rα2
against GBM. The authors demonstrated that TanCAR T
cells have a synergistic effect in eliminating glioma cells
when compared to CAR T cells individually targeting
either IL13Rα2 or HER2 antigens. In addition, simultaneous binding to both antigens in the TanCAR system has
shown to elicited a significantly higher cytokine response
when compared to that from binding to one antigen
alone.
Bi-specific, trivalent, and tandem CARs are all known
as “OR-gate” CARs, as binding of either CAR to its antigen is sufficient to drive full T cell activation. However,
targeting multiple antigens may increase the safety concern especially when treating solid tumors. More specifically, many antigens that are being targeted with CAR T
cells also are expressed in normal cells at low levels, raising the risk of on-target off-tumor toxicities. To address
such issues, the split CARs, also known as “AND-gate”
CARs, were designed. With this approach, T cells were
engineered to co-express two different CARs, one containing the CD3ζ signal and the other containing the
co-stimulation signal. Recognition of a single antigen in
normal cells will not be enough to activate these CAR T
cells, however, only when bound to both antigens, which
are overexpressed in tumor cells, would the T cells be
fully activated (Fig. 2f ). While not reported in GBM,
Lanitis et al. [34] generated CAR T cells that co-express
anti-mesothelin scFv-CD3ζ and anti-α-folate receptor
(FRα) scFv-CD28 CARs. These AND-gate CAR T cells
showed weak cytokine secretion against the target cells
expressing only one antigen in vitro. When tested in vivo,
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the mesothelin/FRα-CAR T cells showed potent efficacy
against tumors overexpressing both FRα and mesothelin,
but not normal tissues expressing mesothelin alone.
The synNotch CAR is another “AND-gate” CAR [35].
The Notch protein is a transmembrane receptor with an
intracellular domain containing a transcriptional regulator that is released from the membrane when activated
by its ligand. With this mechanism, a synthetic Notch
receptor (synNotch) was designed for binding to the first
antigen for activation of synNotch system, which then
switches-on the transcription of a CAR (synNotch CAR)
to recognize and bind to the second antigen on cancer
cells (Fig. 2g). Thus, overexpression of both antigens is
required to provide the signal needed for CAR T cell killing and activation. While this system has showed functionality in vitro and in in vivo animal models [36, 37],
the applications for brain tumors as well as in clinical trials have not been established.
Genetic modification to improve CAR T cell persistence
and safety

Since CAR T-cell therapy showed promising but limited anti-tumor response in GBM clinical trials in 1990s,
efforts have been made to improve CAR T-cell efficacy.
A strategy is to further engineer T cells to overexpress
transgenic proteins such as cytokines and chemokines
that are known to stimulate T cell proliferation and persistence. Such CAR T cells are also known as “T cells
redirected for universal cytokine-mediated killing”, socalled TRUCKs or the 4th generation CARs [23] (Fig. 1b).
Studies have shown that modifying CAR structures to
overexpress IL-15 or constitutively active IL-7R (C7R)
improved CAR T cell anti-tumor activity and persistence in GBM [38, 39]. A recent study further reported
that an “All-in-One” lentiviral TRUCKs which overexpress IL-12 or IL-18 dependent on CAR T cell activation improved the efficacy of GD2-CAR T cells in GBM
[40]. While these additional CAR T cell modifications
greatly improved CAR T-cell therapy, they pose the risk
of uncontrollable T cell proliferation resulting in potential treatment-related toxicities.
Safety and toxicity have always been a concern since
CAR T-cell therapy entered the clinical trials. The major
reported toxicity is cytokine release syndrome (CRS) as
determined by a rapid and sustained cytokine release
including IL-2, IL-6, IL-10 and IFNγ following T cell activation and expansion [41–43]. However, great progress
has been achieved since tocilizumab, an FDA-approved
anti-IL-6 antibody, showed rapid reversal of severe CRS
syndromes, which has become the standard management
[44].
As mentioned above, split CARs and synNotch CARs
are designed to precisely target tumor cells rather than
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normal tissues, reducing the risk of toxicity. A more specific approach to eliminate unintended adverse effects is
to manage CAR T-cell survival by modifying CAR vectors
to include an inducible “suicide” gene as a safety switch.
For example, Stavrou et al. [45] has reported an approach
using rapamycin administration to activate the expression of caspase 9 (an apoptotic protease) in CAR T cells,
which may drive CAR T cells toward apoptosis when
needed. Notably, use of the inducible caspase 9 safety
switch has entered clinical trials for treating relapsed or
refractory ALL (NCT03016377) and B-cell lymphoma
(NCT03696784). While severe toxicity has not been
reported in GBM clinical trials, methods are being developed to avoid potential risks. Rituximab is a mono-clonal
antibody that targets CD20 cells and leads to the depletion of B lymphocytes. To reduce the potential toxicity
of targeting EphA2 in GBM, Yi et al. [46] showed that
using CD20 as a tag in the CAR vector not only served
as a selection marker for determining CAR T-cell transduction efficacy using flow cytometry, but also acted as
a safety switch. Upon stimulation with rituximab, the
activated CAR T cells can be efficiently eliminated within
24 h of treatment. Other safety switches include EGFR
(targeted by cetuximab) [47, 48], and herpes simplex
virus thymidine kinase (targeted by ganciclovir) [49].

CAR T‑cell therapeutic targets for GBM
CAR T cell targets that are in clinical trials against GBM

CAR T cell targets for brain tumors that have been
evaluated pre-clinically and in early phase clinical trials are IL13Rα2, EGFRvIII, HER2, EphA2, GD2, B7-H3
and chlorotoxin. Below we discuss each of these targets
by reviewing their biology and clinical trial outcomes
(Table 1).
IL13Rα2

Interleukin-13 receptor alpha 2 (IL13Rα2) overexpression occurs in over 75% of GBM tumors, and is associated with invasive glioma growth and poor prognosis
[50]. In normal cells, IL-13 binds to IL13Rα1 monomers
with low affinity, forming a heterodimer with IL4Rα, followed by activating STAT6 to induce the pro-apoptosis
activity. However, in glioma, IL13Rα2 binds to IL-13 with
higher affinity, allowing for sequestration of IL-13 away
from IL13Rα1 [51, 52]. The fact that IL13Rα2 is specifically overexpressed in GBM but not normal tissue and
with higher affinity binding sites than IL13Rα1 has made
it the first CAR T cell target for GBM. Brown et al. have
reported that administration of IL13Rα2-specific CAR
T cells into the post-surgical cavity of GBM patients
resulted in a 7.5-month regression period with a median
overall survival of 11 months without severe toxicity [50,
53]. Despite the initial positive response in clinical trials,
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IL13Rα2-specific CAR T-cell therapy is being challenged
by tumor recurrence due to antigen loss and limited T
cell persistence [50]. Thus, methods aiming at improving
IL13Ra2-specific CAR T-cell efficacy have been evaluated
[38]. In addition, evaluation of the combination therapy
of IL13Rα2-specific CAR T cells with the immune checkpoint inhibitors (ICI), such as nivolumab and ipilimumab,
are in clinical trials (NCT04003649).
EGFRvIII

EGFR is a well-known receptor tyrosine kinase (RTK)
involved in cancer initiation and progression. The
EGFRvIII is the most common EGFR mutation that
occurs in about 45% of GBM patients. EGFRvIII arises
from the deletion of exons 2–7 and has a truncated extracellular domain. This mutation causes constitutive activation of RTK/RAS/AKT signaling which is enhanced in
88% of GBM patients [54]. EGFRvIII is specific to GBM
and is not found in normal tissues. EGFRvIII targeting
inhibitors failed to show significant clinical efficacy in
GBM patients mainly due to signaling bypass, in which
inhibition of EGFR vIII pathway leads to activation of
other RTKs, providing a good reason for further developing EGFR vIII-CAR T-cell therapy [55]. O’Rourke et al.
[41] reported the first study in humans of intravenous
delivery of a single dose of EGFRvIII-CAR T cells in 10
recurrent GBM patients which showed safety and limited
anti-tumor response as well as targeted antigen downregulation. Goff et al. [56] reported a pilot phase I trial with
third generation EGFRvIII-CAR T cells administered
after lymphodepleting chemotherapy and intravenous
interleukin-2 injections. This study did not show significant toxicity but failed to show clinical efficacy. Another
design of EGFRvIII-CAR T cell using humanized scFv
again proved safe but also failed to show clinical benefit [41, 57]. Currently, there are six EGFRvIII-CAR T
cell clinical trials ongoing with two in combination with
chemotherapy or ICI (Table 1).
HER2

HER2 is a member of the EGFR family, also named
as ERBB2. Increased levels of HER2 protein in GBM
patients is linked to poor survival [14, 58, 59]. Unlike
EGFRvIII, which is unique to GBM, HER2 is overexpressed in many cancer types including breast, ovarian
and GBM; it also is expressed in some normal tissues,
leading to safety concerns. An early case report with
HER2-CAR T cell therapy has documented a metastatic
colon cancer patient who experienced respiratory distress within 15 min of HER2-targeting CAR T cell administration and died 5 days after treatment. Serum samples
after cell infusion showed marked increases in interferon
γ (IFNγ), granulocyte macrophage-colony stimulating
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factor (GM-CSF), tumor necrosis factor-alpha (TNFalpha), interleukin-6 and -10 (IL-6 and IL-10), consistent
with a cytokine storm [60]. Since then, efforts have been
made to overcome these safety concerns [61]. Liu et al.
[62] showed that lowering the binding affinity between
scFv and HER2 may increase the differential binding of
CAR T cells to tumor versus normal tissue in preclinical
cancer models, providing a good strategy for targeting
the antigens that are not specific to solid tumors. A more
recent clinical trial (NCT00902044) reported no significant toxicities of a second generation HER2-specific
CAR T-cell therapy for sarcoma [63]. Compared with the
original 4D5 HER2-CAR which binds to the juxtamembrane region of HER2 protein and caused severe toxicity, this trial used a FRP5-HER2 CAR which recognizes a
discontinuous epitope between residues 11–169 of HER2
that is more distant from the cell surface. Thus, the binding site of the epitope also determines the activity of the
CARs. As for GBM, investigators at Baylor College of
Medicine have conducted a clinical trial (NCT01109095)
to evaluate the safety and efficacy of HER2-specific CARs
using virus-specific T cells (CAR-VSTs) [59]; previous
studies have shown that virus engineered cytotoxic T
cells demonstrate better persistence and T cell expansion
through appropriate co-stimulatory signaling activation
[64]. In this trial, overexpression of FRP5 HER2-CARs
in virus-specific T cells not only improved the specific
targeting of HER2+ tumor cells, but also prolonged the
HER2-CAR VST cell persistence and antitumor activity.
While this trial has demonstrated treatment safety, the
clinical benefit was limited.
EphA2

EphA2 protein is overexpressed in gliomas and is associated with malignancy, thus it became a good molecular
target in GBM [65, 66]. Preclinical studies demonstrated
that a second generation EphA2-CAR T cell induced glioma xenograft tumor regression in vivo [46, 67]. So far
one clinical trial was initiated to evaluate the safety and
effectiveness of CAR T cell immunotherapy in treating
patients with EphA2+ malignant glioma but has been
withdrawn recently for unknown reason (NCT02575261).
GD2

GD2 is a glycosphingolipid expressed at low levels on the
surface of healthy cells, but highly expressed on several
tumor types including gliomas and is associated with
increased tumor proliferation and invasion [68]. Pre-clinical studies have demonstrated a robust antigen-dependent cytokine production and killing of 
GD2+-positive
glioma cells in vitro and in vivo using patient-derived
orthotopic xenograft models overexpressing GD2 [16,
17]. Currently, two phase I clinical trials (NCT04099797
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and NCT03423992) are evaluating the safety and efficacy
of GD2-specific CAR T cells in high grade glioma and
diffuse intrinsic pontine glioma (DIPG).
B7‑H3

B7-H3 (CD276) is an immune checkpoint molecule and
a member of B7 protein superfamily. B7-H3 binds to the
majority of neuroepithelial tumors but not to normal glia
or tissues, making it a promising target for therapeutics
[69]. Clinical trials for two mAbs targeting B7-H3 (8H9
and MGA271) have been shown to be safe and promising
for metastatic CNS neuroblastoma and DIPG in children.
[70, 71]. Using a B7-H3 (MGA271) 41BBζ CAR, Majzner
et al. [18] have reported a robust anti-tumor activity in
multiple solid, liquid, and CNS tumor types. In addition,
Nguyen et al. [72] demonstrated that B7-H3-specific
(MGA271) CD28ζ CAR-T cells have potent anti-tumor
activity in U373 glioma model. To date, two GBM-related
clinical trials focused on B7-H3 CAR T-cell therapy
(NCT04385173, NCT04077866) are in the recruitment
phase.
Chlorotoxin

Chlorotoxin (CLTX) is a 36-amino acid peptide first
isolated from scorpion venom that specifically binds to
GBM but not to normal tissue. Pharmacologically, CLTX
binds to and blocks small-conductance chloride channels
[73]. Unlike the common CARs that are designed to recognize surface TAAs to kill tumor cells, the CLTX-CAR
was designed as a peptide-based CAR to recapitulate the
GBM-binding potential of CLTX. With this approach,
Wang et al. [19] showed that CLTX-CAR T cells mediate
potent anti-GBM activity and efficiently targeted tumors
lacking expression of other GBM-associated antigens,
resulting in tumor regression in orthotopic xenograft
GBM tumor models. Importantly, the CLTX-CAR-T cells
exhibited minimal off-target effects, without showing
toxicity following systemic or regional delivery into mice.
Given the finding that effective targeting by CLTX-CAR
T cells requires cell surface expression of matrix metalloproteinase-2 (MMP2), a clinical trial has been initiated
for treating 
MMP2+ recurrent GBM (NCT04214392).
More importantly, this study also opened a new avenue
to repurpose the use of a natural toxin for CAR T cell
engineering.
Other potential CAR T cell targets for GBM

While the current CAR T cell targets continue to be
developed and improved, progress also is being made
in exploring new targets specific for GBM. Below we
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review other promising brain TAAs that have been tested
pre-clinically.
CD70

CD70 is a type II transmembrane protein and a member of the tumor necrosis factor family. CD70 was not
detected in normal peripheral and brain tissues but was
constitutively overexpressed in isocitrate dehydrogenase
(IDH) wild-type primary low-grade gliomas, and GBMs
in the mesenchymal subgroup and recurrent tumors.
CD70 is associated with poor survival in GBM patients
making it a good candidate for CAR T-cell therapy [74,
75]. Several pre-clinical studies with differently designed
CD70-specific CAR-T cells have shown robust antitumor response against C
 D70+ mouse models [74, 76].
While there is no current clinical trial for testing CD70specific CAR-T cells in GBM, phase I/II clinical trials are
underway to study the safety and efficacy of CD70-specific CAR-T cell therapy in B cell cancers (NCT03125577,
NCT04429438) as well as pancreatic, renal, breast and
ovarian cancers (NCT02830724).
CD133

CD133 is a marker for self-renewing cancer stem cells
(CSCs) in solid tumors. CD133+ tumor cells, including
GBM, are known to be highly resistant to chemo- and
radiotherapy. Recently, CD133 has been identified as a
potential CAR T cell target for treatment of GBM. While
CD133 also is expressed on hematopoietic stem and progenitor cells (HSPC), Vora et al. [77] demonstrated that
intra-tumoral injections of CD133-specific CAR T cells
are effective at eliminating GBM and that this treatment
does not cause systemic toxicity in humanized mouse
models. In addition, in a phase 1 clinical trial (NTC
02541370) CD133-specific CAR T cells showed feasibility and efficacy against advanced metastatic malignancies
with no serious adverse effects, further confirming the
therapeutic potential of targeting CD133 [78].
MET

MET is the receptor of hepatocyte growth factor (HGF),
and a well-known RTK being developed as an anti-cancer target. HGF/MET overexpression frequently occur
in GBM patients and is associated with poor prognosis
[54, 79, 80]. Using a transgenic mouse model, Qin et al.
[81] showed that overexpression of HGF and MET may
transform neuro stem cells into glioma stem cells (GSCs),
leading to GBM initiation. GBM harboring MET amplification or HGF autocrine activation are sensitive to
MET inhibitors in preclinical models [82, 83], recent
clinical trials further showed that a combination of MET
and VEGF inhibitors (ontarzucimab plus bevacizumab
vs. placebo plus bevacizumab) significantly improved
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progression free survival (PFS) and overall survival (OS)
in the mesenchymal subtype of recurrent GBM patients
with high tumor HGF expression [84]. These results suggest that MET maybe a good target for CAR T-cell therapy in GBM.
Summary for CAR T cell targets in GBM

Although a large number of CAR T cell targets under
development for treating GBM are showing promising
preclinical results, limited antitumor response has been
observed in clinical trials, largely due to limited T cell
persistence and antigen-negative relapses. While technical innovations to improve the CAR T cell expansion,
survival, efficacy and safety remain the key next steps to
pursue, combination with other therapies also have been
comprehensively considered to improve the CAR T cell
therapy [85]. Below, we introduce the combination with
ICIs as a promising approach to overcome T cell exhaustion which in turn may improve CAR T cell efficacy in
clinical trials.

CAR T cell therapy in combination with immune
checkpoint inhibitors
The tumor microenvironment is orchestrated by immunosuppressive cytokines, regulatory modulators and
co-inhibitory receptors that regulate the responsiveness
of immune cells [86]. While active CAR T cells elicit
specific recognition and killing activities against tumor
cells, the chronic exposure to tumor cells results in T
cell exhaustion mediated by immune checkpoint pathway activation that is initiated by tumor cells, leading
to a reduced ability to proliferate, produce cytokines and
attack the tumor (Fig. 1c). Exhausted T cells upregulate
immune inhibitory receptors, such as programmed death
ligand-1 (PD-L1) and cytotoxic T lymphocyte-associated
antigen 4 (CTLA-4). Blocking this immune suppressive signaling has led to the development of ICIs such as
nivolumab and durvalumab (PD-1/PD-L1 inhibitors) and
ipilimumab (CTLA-4 inhibitors). These ICIs are FDAapproved for treating several types of cancer including
melanoma, hepatocellular carcinoma and lymphoma
and have shown significant clinical results [87]. Since
ICIs eliminate T cell exhaustion, combining their use
may further enhance CAR T-cell therapy efficacy through
extended T cell proliferation and sustained tumor-killing
activity. A recent case report has shown that administration of the PD-1/PD-L1 inhibitor pembrolizumab after
CD19-specific CAR T-cell therapy in refractory diffuse
large B-cell lymphoma induced a clinically significant
antitumor response, suggesting that the PD-1 pathway
may be critical in determining the response to CARmodified T-cell immunotherapy [88]. However, despite
the promising clinical results in other types of cancer, the
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use of ICIs in GBM clinical trials remain controversial.
Nivolumab, a PD-1/PD-L1 inhibitor, failed to prolong
overall survival of patients with recurrent GBM, leading to a discussion of whether ICIs may benefit GBM
patients after all [89–91]. Nevertheless, a recent trial with
35 patients with recurrent, surgically-removable GBM
showed that patients who receive neoadjuvant PD-1
blockade, with continued adjuvant therapy following surgery had significantly better overall survival compared
to those who received adjuvant or post-surgical PD-1
blockade alone [92]. Another study also suggests that
combination of local chemotherapy with PD-1 blockade
enhanced antigen-specific T effector cell expansion and
improves survival in GBM models [93]. These studies
suggest that anti-PD-1 blockade alone may not directly
benefit GBM patients but may improve the efficacy of
other therapeutics when used in combination. Currently,
clinical trials are on-going to evaluate the therapeutic
efficacy of EGFRvIII-CAR (NCT03726515) and IL13Rα2CAR (NCT04003649) T-cell therapy in combination with
ICIs such as pembrolizumab or nivolumab in recurrent
or refractory GBM patients (Table 1). We anticipate that
anti-PD1 blockage may improve the CAR T-cell efficacy
for treating GBM patients.

Future perspectives
Over the past decades, we have learned key principles
to manage CAR T-cell efficacy: the specificity of the targeted antigen, the sufficient TCR activation by the specific antigen binding domain, the level of T cell activation
and longevity, and the hostile micro-environment for T
cells to penetrate, which also serves a source of immunosuppressive factors [94]. While many types of CAR T
cells are now in clinical trials (Table 1), further optimization with advanced approaches are expected to improve
their overall clinical efficacy.
Since genetic modification of CAR vectors is showing promising results in improving CAR T-cell efficacy,
gene editing of the T cell is now a new strategy to further improve CAR T cells. Recently, the CRISPR/Cas9
mediated gene editing system has been applied to delete
or mutate checkpoint-associated genes in CAR T cells,
and has shown improvement in T cell persistence and
survival [95–97]. Using CRISPR/Cas 9-mediated deletion, Ren et al. [95] generated CD19-CAR T cells simultaneously deficient in TCR, HLA class I molecule and
PD1, which showed more potent antitumor activities
than non-edited CAR T cells when tested in xenograft
mouse models. Notably, the TCR and HLA class I double-deficient T cells further reduced MHC restriction
and eliminated alloreactivity and potential graft-versushost disease (GVHD), thus making the strategy particularly useful for treating different patients. A different
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study using CRISPR/Cas9-mediated deletion of TCR α
subunit constant (TRAC) region, beta-2 microglobulin (B2M) and PD-1 also showed profound anti-tumor
activity in vivo [97]. Recently, Li et al. [98] investigated
the approaches to improve CAR T transduction efficacy and CRISPR/Cas9 mediated PD-1 deletion using a
2-in-1 lentivirus vector and found that blocking anti-viral
signaling in human primary T cells enhanced lentiviralmediated transduction efficacy of a combinatory CAR/
CRISPR vector for targeting HER2 and inhibiting PD-1 at
the same time. Most importantly, the first phase 1 clinical
trial using CRISPR/Cas9 for multiplex gene editing on T
cells (NCT03399448) has demonstrated safety and feasibility in three patients with refractory cancer [99]. Given
that the CRISPR/Cas9 approach has been widely applied
to functional gene screening and validation, it also opens
a new avenue to discover and target novel modulators of immune suppression. Through CRISPR/Cas9mutagenesis screening, Wei et al. [100] have identified
Regnase-1 as a major negative regulator of anti-tumor
responses in CD8+ T cells, and that CD19-CAR T cells
with deleted Regnase-1 showed greater longevity and a
more vigorous anti-tumor response in B16 ovarian and
B6 melanoma mouse models. We anticipate that future
GBM-specific studies also will explore these novel ideas
and approaches, which hopefully will further enhance
CAR T-cell proliferation, longevity and long-term antitumor activity.

Conclusion
Brain tumors are considered one of the “most-difficultto- treat” solid tumors. With the most recent advances
in immunotherapy, the CAR T-cell therapy has become a
revolutionary approach for treating hematological malignancies and it has great potential for brain tumors. This
review intends to introduce interpretations of the most
relevant papers addressing the use of CAR T cells for the
treatment of GBM. We discussed the CAR designs and
optimization, the major CAR T cell targets in clinical trials, as well as the strategies developed to improve CAR-T
cell efficacy in the context of GBM. We anticipate that
future clinical trial designs will not only focus on efficacy
and safety, but also on the mechanisms involved in the
immune response and resistance, and that the next generation of CAR T cell therapy will become an effective
and safe therapeutics for treating malignant GBM.
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